Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHD-286 in Metastatic Uveal Melanoma
NCT04879017Phase 1Terminated
- Sponsor
- Foghorn Therapeutics
- Start
- May 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of camibirstat in Uveal melanoma (UM), sponsored by Foghorn Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events at 31 months, Incidence of adverse events and serious adverse events at 31 months and 1 more. Started May 2021; status: terminated.
02
Drugs
camibirstat
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04879017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879017.